IL15 and neoplasm: The combination regimen (B7-H6M4-LC21 + IL-15 fusion) significantly enhanced tumor suppression versus monotherapies (achieved 76.1% ± 14.8% tumor growth inhibition; p < 0.05; Figures 7E, F) without significant weight changes at therapeutic doses.